Journal
MEDICAL ONCOLOGY
Volume 35, Issue 7, Pages -Publisher
HUMANA PRESS INC
DOI: 10.1007/s12032-018-1156-x
Keywords
Malignant pleural mesothelioma; Immunotherapy; Immune checkpoint inhibitors; CAR T cell therapy
Categories
Ask authors/readers for more resources
Malignant pleural mesothelioma (MPM) is a very aggressive malignancy, mainly caused by asbestos exposure. Patients with MPM have a poor prognosis that remained substantially unchanged in the last few years and limited effective therapeutic options with no recognized second or further-line therapy. In this context, also in view of the positive results observed in other tumor types, immunotherapy could play a relevant role. This review focuses on the most promising immunotherapies being investigated in MPM.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available